Effects of Ulinastatin on Myocardial Protection and Blood Loss in Patients Undergoing Aortic Valve Replacement

Yonsei University

Status and phase: Completed; Phase 4

Conditions: Abnormal Aortic Valve

Treatments: Drug: ulinastatin

Study type: Interventional

Funder types: Other

Identifiers

NCT00944385

4-2009-0079

Details and patient eligibility

About

According to TEG (thromboelastography), as maximum amplitude is increased the amount of bleeding and transfusion and Cardiac enzyme is reduced by using ulinastatin.

Sex: All

Ages: 20 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• 40% below of output of left ventricle
• tricuspid valve failure from moderate to severe
• urgent surgery required
• infectious endocarditis

Trial design

0 participants in 2 patient groups, including a placebo group

ulinastatin

Experimental group

Description:

Administer with 30,000U /ulinastatin

Treatment:

Drug: ulinastatin

C group

Placebo Comparator group

Description:

administer normal saline

Treatment:

Drug: ulinastatin